Skip to content

Late In-the-bag intraOcular Lens dislocatioN Surgery

Late In-the-bag intraOcular Lens dislocatioN Surgery: A Randomized Clinical Trial (LION Trial)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03276104
Acronym
LION
Enrollment
50
Registered
2017-09-08
Start date
2017-09-09
Completion date
2022-12-31
Last updated
2019-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraocular Lens Dislocation

Keywords

IOL dislocation, Cataract, Cataract surgery, Scleral suturing, Verisyse, Iris-claw, Late in-the-bag IOL dislocation

Brief summary

Overall aim of the study is to compare the safety and efficacy of two different surgical methods to treat Late In-the-bag intraocular lens dislocation.

Detailed description

Cataract is a condition of unclear lens that cause poor vision. The only treatment is surgery where the blurred biological lens is replaced with an artificial clear lens (IOL). Most people who operate achieve full vision. Nevertheless, serious complications may occasionally occur, and one of these is dislocation of the entire complex with IOL and lens capsule. This requires surgical treatment. In this study the investigators want to compare two different surgical methods used in late dislocation of IOL inside the capsule after cataract surgery. Patients will be randomly affiliated to either the suturing of existing IOL / capsule complex, or lens exchange to an IOL fixed to the iris. The focus of the trial will be especially on complications and other eye changes in the early stages of surgery. Today, little data is available on these topics, and the investigators believe that new knowledge can bring us closer to a response to preferred operating techniques and an optimal drug drop regime for the patient group.

Interventions

PROCEDUREIOL repositioning

Intraocular lens repositioning by scleral suturing

PROCEDUREIOL exchange

Intraocular lens exchange with retropupillary iris-claw lens

Sponsors

South-Eastern Norway Regional Health Authority
CollaboratorOTHER
Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Masking of research optometrists to group affiliation at the postoperative examinations will be endeavored. A physician will perform slit lamp examinations at the postoperative visits, hence he/she cannot be masked, nor can the surgeon. The investigator will be masked during the image analysis.

Intervention model description

Randomized clinical trial

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* IOL inside the capsule (in-the-bag) * Late dislocation (more than 6 months after cataract surgery) * IOL visible in the pupillary area in the supine position and hence possible to perform surgery with an anterior approach * Eligibility for both operation methods * Ability to cooperate fairly well during the examinations * Willing to participate in the study, e.g. willingness to participate at all control visits

Exclusion criteria

* IOL designs that cannot be repositioned with a suture loop, such as plate-haptic IOLs without holes in the peripheral part * Eyes with especially thin sclera * Active uveitis or pronounced iris pathology * Eyes with previously performed Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) * Totally dislocated IOL into the posterior segment of the eye requiring pars plana vitrectomy * Eyes that prior to cataract extraction had a subluxated lens in need of surgery with a Cionni capsular tension ring (e.g. patients with Marfan syndrome and ectopia lentis) * Cases requiring a change in refraction. Risk of severe anisometropia * Patients unable to lie in supine position for surgery in local anesthesia, e.g. severe chronic obstructive pulmonary disease and severe heart failure * Patients using anticoagulants that cannot be discontinued For patients with dislocated IOLs in both eyes during the study period, only the first operated eye will be included. Patients without prospects of improvement in vision will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Inflammation in the anterior chamber after surgeryThe first weeks after surgeryMeasured with a Laser Flare Meter
Changes in macular thickness and occurrence of Cystoid macular edemaThe first months after surgery, and long term changes months up to two years after surgeryEvaluated with Optical Coherence Tomography
Intraocular pressure changesEarly changes in the first weeks after surgery, and long term changes months up to two years after surgeryMeasured with Goldmann Applanation Tonometry and iCare, both measured in mmhg

Secondary

MeasureTime frameDescription
Intra- and postoperative complicationsShort term and long term (first post operative day, the first weeks and months, and up to two years)All relevant complications
IOL tilt6 months and 2 yearsMeasured with anterior segment Ultra Sound
Best Corrected Visual acuity (BCVA)Short term (the first weeks and up to 6 months) and long term (up to two years)Measured in LogMar
AstigmatismShort term - meaning 2 weeks to 6 months. Long term - meaning up to two yearsTo compare astigmatism measured by keratometry
Refractive outcomes - subjective refraction measured with a phoropterShort term - meaning 2 weeks to 6 months. Long term - meaning up to two yearsTo compare the refractive outcomes (short and long-term)
GlareMedium term (6 months)Measured by straylight meter
Endothelial cellsShort term (2 weeks) and long term (6months and 2 years)Measured by Non-contact corneal confocal microscopy

Countries

Norway

Contacts

Primary ContactMarius Dalby, M.D. PhD Cand.
marius.dalby@gmail.com+47 92408957

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026